Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial

International Journal of Cardiology

Volumn 212, Issue , 2016, Pages 110-117

  Crimi, Gabriele ^a   Leonardi, Sergio ^a   Costa, Francesco ^b   Adamo, Marianna ^b   Ariotti, Sara ^c   Valgimigli, Marco ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

2nd generation drug eluting stent; Chronic kidney disease; Drug eluting stent; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; METAL; TICLOPIDINE;

ADULT; AGED; ARTICLE; BARE METAL STENT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; EVEROLIMUS ELUTING CORONARY STENT; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PACLITAXEL ELUTING CORONARY STENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; STENT THROMBOSIS; TREATMENT DURATION; ZOTAROLIMUS ELUTING CORONARY STENT; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; CORONARY THROMBOSIS; DEVICES; DRUG ELUTING STENT; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIAL; RENAL INSUFFICIENCY, CHRONIC; STENT; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ASPIRIN; CLINICAL DECISION-MAKING; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; METALS; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RENAL INSUFFICIENCY, CHRONIC; STENTS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84961943300     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.033     Document Type: Article

References (26)

1. C.S. Fox, P. Muntner, A.Y. Chen, and et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: A report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry Circulation 121 2010 357 365
2. J.B. Washam, C.A. Herzog, A.L. Beitelshees, and et al. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: A scientific statement from the American Heart Association Circulation 131 2015 1123 1149
3. T.T. Tsai, J.C. Messenger, J.M. Brennan, and et al. Safety and efficacy of drug-eluting stents in older patients with chronic kidney disease: A report from the linked CathPCI Registry-CMS claims database J. Am. Coll. Cardiol. 58 2011 1859 1869
4. A.J. Saltzman, G.W. Stone, B.E. Claessen, and et al. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: The HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial J. Am. Coll. Cardiol. Intv. 4 2011 1011 1019
5. I. Iakovou, T. Schmidt, E. Bonizzoni, and et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents JAMA 293 2005 2126 2130
6. Y. Miao, Z. Yu-Jie, W. Zhi-Jian, and et al. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents Catheter. Cardiovasc. Interv. 80 2012 361 367
7. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS), European Association for Percutaneous Cardiovascular Interventions (EAPCI), W. Wijns, and et al. Guidelines on myocardial revascularization Eur. Heart J. 31 2010 2501 2555
8. B.K. Kim, S. Oh, D.W. Jeon, and et al. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) Registry J. Interv. Cardiol. 22 2009 411 419
9. A.I. Syed, I. Ben-Dor, S.D. Collins, and et al. Sirolimus-eluting stents versus paclitaxel-eluting stents in patients with chronic renal insufficiency J. Interv. Cardiol. 23 2010 33 39
10. S.M. Green, F. Selzer, S.R. Mulukutla, and et al. Comparison of bare-metal and drug-eluting stents in patients with chronic kidney disease (from the NHLBI Dynamic Registry) Am. J. Cardiol. 108 2011 1658 1664
11. C. Shenoy, J. Boura, P. Orshaw, and K.J. Harjai Drug-eluting stents in patients with chronic kidney disease: A prospective registry study PLoS One 5 2010 e15070
12. M. Valgimigli, G. Campo, M. Monti, and et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial Circulation 125 2012 2015 2026
13. M. Valgimigli, M. Borghesi, M. Tebaldi, and et al. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur. Heart J. 34 2013 909 919
14. M. Valgimigli, G. Campo, G. Percoco, and et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY) Am. Heart J. 160 2010 804 811
15. D.E. Cutlip, S. Windecker, R. Mehran, and et al. Clinical end points in coronary stent trials: A case for standardized definitions Circulation 115 2007 2344 2351
16. The R Core Team R: A Language and Environment for Statistical Computing 2014 2014 R Foundation for Statistical Computing Vienna, Austria http://www.R-project.org/
17. M.J. Landray, D.C. Wheeler, G.Y. Lip, and et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: The chronic renal impairment in Birmingham (CRIB) study Am. J. Kidney Dis. 43 2004 244 253
18. E.L. Schiffrin, M.L. Lipman, and J.F. Mann Chronic kidney disease: Effects on the cardiovascular system Circulation 116 2007 85 97
19. M. Sabate, A. Cequier, A. Iniguez, and et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial Lancet 380 2012 1482 1490
20. L. Raber, H. Kelbaek, M. Taniwaki, and et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: Two-year clinical results of the COMFORTABLE AMI trial Circ. Cardiovasc. Interv. 7 2014 355 364
21. T. Palmerini, G. Biondi-Zoccai, D. Della Riva, and et al. Stent thrombosis with drug-eluting and bare-metal stents: Evidence from a comprehensive network meta-analysis Lancet 379 2012 1393 1402
22. D.J. Angiolillo, E. Bernardo, D. Capodanno, and et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy J. Am. Coll. Cardiol. 55 2010 1139 1146
23. P.J. Best, S.R. Steinhubl, P.B. Berger, and et al. The efficacy and safety of short- A nd long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am. Heart J. 155 2008 687 693
24. A. Dasgupta, S.R. Steinhubl, D.L. Bhatt, and et al. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial) Am. J. Cardiol. 103 2009 1359 1363
25. S.D. Wiviott, E. Braunwald, C.H. McCabe, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
26. L. Wallentin, R.C. Becker, A. Budaj, and et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 361 2009 1045 1057